Comparison between Antipsychotic Drug and its Nano-Emulsion on Neurochemical and Behavioral Disorders on an Animal Model of Schizophrenia and its Adverse Effects
Background: The present work was carried out to study the effect of olanzapine (OLZ) and its solid lipid nanoparticles
(SLN) on ketamine-induced schizophrenic-like symptoms in albino rats. The study extended to evaluate the adverse effects
of sub-chronic administration of the different doses of olanzapine and its solid lipid nanoparticles.
Methods: To assess the effect of different doses of treatment on locomotor activity and cognitive impairment induced by
ketamine open field and passive avoidance tests was carried out. Excitatory and inhibitory amino acids as well as dopamine
and serotonin were estimated in brain regions. Immunohistochemical study of BCL2 was performed. Liver function, lipid
profile and lipid peroxide, then assessed to evaluate the side effect.
The results: administrations of OLZ-SLN at low and high doses before ketamine attenuated the behavioral abnormalities by
inhibiting the ketamine-induced increased in glutamate, dopamine and serotonin levels and enhanced apoptosis in the studied
brain areas. In addition, the sub-chronic treatment with OLZ-SLN showed no adverse effect while the treatment with OLZ
free form did.
Conclusion: The low and high dose of OLZ-SLN that equivalent to (1/10 and 1/20 from the therapeutic dose) blocked the
effect of ketamine while the same doses of OLZ in free form cannot.
Keywords - Solid lipid nanoparticles; Antipsychotic drugs; hepatotoxicity; Excitatory and inhibitory amino acids;